# Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer

> **NCT05889390** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Semmelweis University** · enrollment: 71 (actual)

## Conditions studied

- HER2-negative Breast Cancer

## Interventions

- **DEVICE:** Oncotherm EHY-2030
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Cyclophosphamide/Doxorubicin
- **PROCEDURE:** Breast cancer removal surgery

## Key facts

- **NCT ID:** NCT05889390
- **Lead sponsor:** Semmelweis University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-20
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05889390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05889390, "Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05889390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*